|
Seroconversion rates (percentage of subjects with seroconversiona or a significant increase in HI titresb in subjects without pre-vaccination immunoprotection) |
||
| Seroconversion rates, % |
||
|
|
||
| Viral strain |
Sub/MF59™ |
Subunit |
|
|
||
| A/H1N1c |
83.3 |
80.0 |
| A/H3N2d |
85.1* |
66.2 |
| Be |
33.4 |
25.8 |
|
aSeroconversion is defined as negative pre-vaccination serum (i.e. haemagglutinin inhibition [HI] titre <1:10) and post-vaccination HI titre ≥ 1:40; bSignificant increase is defined as ≥ 4-fold increase from non-negative (≥ 1:10) pre-vaccination HI titre; cNumber of subjects: Sub/MF59™, 6; Subunit, 5; dNumber of subjects: Sub/MF59™, 288; Subunit, 152; eNumber of subjects: Sub/MF59™, 359; Subunit, 183 *P < 0.001 versus the Subunit group Sub/MF59™, MF59™-adjuvanted subunit influenza vaccine; Subunit, non-adjuvanted subunit influenza vaccine | ||
Li et al. Immunity & Ageing 2008 5:2 doi:10.1186/1742-4933-5-2 |
||